Company intelligence / Profile preview
Flashpoint Therapeutics
Palo Alto, California, United Statesflashpoint.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead program FLASH-001 has demonstrated a curative effect in a small subset of Merkel Cell Carcinoma patients in phase 1b/2 trials. The company plans to expand studies in 2025 to larger patient cohorts and additional cancer types.
- Therapeutic areas
- OncologyDermatologyNeurology
- Modalities
- RNADNApeptidesCRISPRnucleic acidsnanotechnology-enabled therapeutics
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
KAIMRC (King Abdullah International Medical Research Center)Northwestern UniversityHolden PharmaceuticalsExicure
Beyond the preview
Go deeper on Flashpoint Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flashpoint Therapeutics.